This clinical trial evaluates the safety and efficacy of Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with acute ST elevation myocardial infarction. The study is conducted by Ruijin Hospital and aims to address the poor prognosis associated with this condition despite standard treatments.